Expert Discusses the Safety of Vemurafenib
At the 2019 Hairy Cell Leukemia Foundation Annual Conference new findings showed promise in the safety of vemurafenib to treat patients with hairy cell leukemia.
Olanzapine Significantly Reduces CINV in Patients Receiving MEC
Reimagining Frailty Screenings in Head and Neck Cancer
Screening for Pain and Depression is Not Enough in Cancer Care
Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC
